1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Continuous Renal Replacement Therapy Market by Products, Modality and Geography - Regional Adoption and Global Forecasts to 2020

The global CRRT market is estimated to grow at a CAGR of 7.2% from 2015 to 2020. Although mature markets such as the U.S., Germany, and the U.K. held larger shares in the CRRT market in 2015, Asia-Pacific is poised to grow at the highest CAGR of 8.7% in the next five years. Factors such as increasing aging population, rise in sepsis cases, growing focus of multinational companies on emerging markets, improvements in and the modernization of healthcare infrastructure, and high incidences of AKI cases in this region are propelling the growth of this market.

The overall growth of the CRRT market is driven by factors such as the rising prevalence of AKI, increasing prevalence of sepsis, growing number of ICU patients, rapid rise in aging population, clinical advantages of CRRT over intermittent blood purification techniques, and the preference for CRRT (it is held as a gold standard for the treatment of hemodynamically unstable patients). However, factors such as high complexity of therapy, high procedural cost of CRRT, stringent regulatory guidelines for CRRT in North America, and the dearth of trained ICU nurses are restraining the growth of this market. Moreover, emerging markets (such as China, India, Brazil, and Mexico); broadening application horizons of CRRT, ongoing researches to establish the safety and efficacy profile of CRRT, and the development of a CRRT system for pediatric patients are creating opportunities for the players involved in the market.

In this report, the global CRRT market has been segmented on the basis of product [CRRT systems, CRRT disposables (hemofilters, bloodlines, and other disposables), and dialysate and replacement fluids] and modality [slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF)].

Geographically, Europe (comprising Germany, France, the U.K., and Rest of Europe) commanded the largest share of 41% of the global CRRT market in 2015, followed by North America. The European CRRT market is primarily driven by various factors such as the increasing cases of AKI in this region and rising aging population, approvals for CRRT machines and anti-coagulating agents in Europe for multiple applications, high utilization rate of CRRT products in Europe, prescription of CRRT products by intensivists in Europe, and research studies and controlled clinical trials to obtain efficacy and safety profile of CRRT products. However, the inconsistent reimbursement scenario for CRRT procedure across European countries is one of the major factors restraining the growth of the CRRT market in this region.

The global CRRT market is highly consolidated in nature. Baxter International Inc. (U.S.) dominated the global CRRT market, with a share of ~55% in 2014, followed by Fresenius Medical Care AG & Co. KGaA (Germany). Other players include Asahi Kasei Medical Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Bellco S.r.l. (Italy), Infomed SA (Switzerland), Medica S.p.A (Italy), Medical Components, Inc. (U.S.), Nikkiso Co., Ltd (Japan), NxStage Medical, Inc. (U.S.), and Toray Medical Company Limited (Japan). Product approvals, launches, and enhancements; acquisition; and geographical expansion are the major strategies adopted by market players to achieve growth in the CRRT market.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysis such as industry analysis (industry trends and Porter’s five forces model), market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the CRRT market, high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help them garner a greater market share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on CRRT products offered by the top 10 players in the CRRT market. The report analyzes the CRRT market by product and modality across geographies

- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the CRRT market

- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for CRRT products across geographies

- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CRRT market

- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the CRRT market

Table Of Contents

Continuous Renal Replacement Therapy Market by Products, Modality and Geography - Regional Adoption and Global Forecasts to 2020
TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH METHODOLOGY STEPS 20
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 21
2.2.1 SECONDARY RESEARCH 21
2.2.1.1 Key data from secondary sources 21
2.2.2 PRIMARY RESEARCH 22
2.2.2.1 Key data from primary sources 23
2.2.2.2 Key industry insights 24
2.3 MARKET SIZE ESTIMATION METHODOLOGY 26
2.4 MARKET DATA VALIDATION AND TRIANGULATION 29
2.5 ASSUMPTIONS FOR THE STUDY 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 37
4.1 MARKET POTENTIAL 37
4.2 MARKET OPPORTUNITY 38
4.3 CRRT MARKET, BY PRODUCT AND MODALITY (2015 VS. 2020) 38
4.4 CRRT MARKET, BY MODALITY (2015) 39
4.5 CRRT MARKET, BY COUNTRY (2015 VS. 2020) 40
5 MARKET OVERVIEW 41
5.1 INTRODUCTION 41
5.2 MARKET SEGMENTATION 42
5.2.1 BY PRODUCT 42
5.2.2 BY MODALITY 43
5.3 MARKET DYNAMICS 43
5.3.1 DRIVERS 44
5.3.1.1 Increasing prevalence of AKI 44
5.3.1.2 Rising adoption of CRRT for the treatment of renal disorders 44
5.3.1.3 Growing number of ICU patients 45
5.3.1.4 Rapid rise in aging population 45
5.3.1.5 Clinical advantages of CRRT over intermittent blood purification techniques 46
5.3.1.6 CRRT is a gold standard for treatment of hemodynamically unstable patients 46
5.3.1.7 Technological advancements and new product launches 46
5.3.1.8 Increasing prevalence of sepsis 47
5.3.2 RESTRAINTS 48
5.3.2.1 High complexity of therapy 48
5.3.2.1.1 Lack of standard treatment guidelines 48
5.3.2.1.2 Complications associated with CRRT 49
5.3.2.2 High procedural cost of CRRT 49
5.3.2.3 Stringent regulatory guidelines for CRRT in North America 50
5.3.2.4 Dearth of trained ICU nurses 50
5.3.3 OPPORTUNITIES 51
5.3.3.1 Emerging markets 51
5.3.3.2 Broadening application horizon of CRRT 51
5.3.3.2.1 Evolution of CRRT from simple renal replacement treatment to a multi-organ support therapy (MOST) 51
5.3.3.2.2 CRRT: Progression from adaptive renal devices to multipurpose treatment machines 52
5.3.3.3 Ongoing researches to establish safety and efficacy profile of CRRT 52
5.3.3.4 Development of a CRRT system for pediatric patients 53
5.3.3.4.1 The CARPEDIEM project 53
5.3.3.5 Untapped market growth opportunities in North America 53
5.3.4 CHALLENGES 55
5.3.4.1 Poor reimbursement scenario in developing countries 55
5.3.4.2 Lack of substantial clinical evidences supporting efficacy of CRRT 55
5.3.4.3 Currently approved CRRT technology is inadequate for children 55
5.3.4.4 Lack of awareness about the benefits of CRRT 55
5.3.5 WINNING IMPERATIVES 56
5.3.5.1 Selling machines along with disposables to end users. 56
5.3.5.2 High bargaining margins on disposables as well as machines 56
5.3.5.3 Development of CRRT machine that is only compatible with respective company's disposables 57
5.3.5.4 Core competency of players 57
5.3.6 INDUSTRY TRENDS 57
5.3.6.1 Training programs for the operation of CRRT devices 57
5.3.6.2 Rising adoption of user-friendly CRRT machines 58

6 INDUSTRY INSIGHTS 59
6.1 INTRODUCTION 59
6.2 REIMBURSEMENT SCENARIO 60
6.2.1 NORTH AMERICA 60
6.2.2 EUROPE 60
6.2.3 ASIA-PACIFIC (EXCLUDING JAPAN) 61
6.2.4 JAPAN 62
6.2.5 REST OF THE WORLD 62
6.3 REGULATORY LANDSCAPE 63
6.3.1 NORTH AMERICA 63
6.3.2 EUROPE 63
6.3.3 ASIA-PACIFIC 64
6.3.4 REST OF THE WORLD 64
6.4 PORTER'S FIVE FORCES ANALYSIS 65
6.4.1 COMPETITIVE INTENSITY 66
6.4.2 BARGAINING POWER OF BUYERS 66
6.4.3 BARGAINING POWER OF SUPPLIERS 66
6.4.4 THREAT OF SUBSTITUTES 66
6.4.5 THREAT OF NEW ENTRANTS 66
6.5 PRICING AND COST ANALYSIS 67
6.6 STRATEGIC RECOMMENDATIONS 68
6.6.1 DESIGN RECOMMENDATIONS FOR CRRT MACHINES 68
6.6.2 KEY STRATEGIES FOR PLAYERS SEEKING TO ENTER THE CRRT MARKET 69
7 ADOPTION OF CRRT, BY REGION 70
7.1 INTRODUCTION 70
7.2 UTILIZATION OF CRRT PROCEDURES, BY REGION 70
7.3 NUMBER OF CRRT PATIENTS, BY REGION 73
8 CRRT MARKET, BY PRODUCT 74
8.1 INTRODUCTION 75
8.1.1 DIALYSATE AND REPLACEMENT FLUIDS 76
8.1.2 CRRT DISPOSABLES 78
8.1.2.1 Hemofilters 81
8.1.2.2 Bloodline Sets (Tubing Sets) 81
8.1.2.3 Other Disposables 82
8.1.3 CRRT SYSTEMS 82
9 CRRT MARKET, BY MODALITY 85
9.1 INTRODUCTION 86
9.2 CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH) 87
9.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF) 89
9.4 CONTINUOUS VENOVENOUS HEMODIALYSIS (CVVHD) 92
9.5 SLOW-CONTINUOUS ULTRAFILTRATION (SCUF) 94
10 CRRT MARKET, BY REGION 96
10.1 INTRODUCTION 97
10.2 CRRT MARKET, BY REGION 99
10.2.1 EUROPE 99
10.2.1.1 CRRT machines approved for multiple applications 101
10.2.1.2 Intensivists' preference for CRRT for AKI treatment 101
10.2.1.3 Players focus on leveraging growth opportunities in Europe 101
10.2.1.4 Germany 104
10.2.1.4.1 Rising focus of players on the German CRRT market 104
10.2.1.5 U.K. 105
10.2.1.5.1 Rising awareness about AKI in U.K. 105
10.2.1.6 France 106
10.2.1.6.1 Symposia and conferences 106
10.2.1.7 Rest of Europe 108
10.2.1.7.1 Clinical research and trials driving market growth in RoE 108
10.2.2 NORTH AMERICA 109
10.2.2.1 North American utilization of CRRT lower than that of Europe, Australia, and Japan 111
10.2.2.2 Regulatory policies, a key hindrance to market growth 112
10.2.2.3 U.S. 113
10.2.2.3.1 Prevalence of AKI, ESRD rising due to growth in aging population 113
10.2.2.3.2 Technological advancement to boost demand for CRRT products 114
10.2.2.3.3 Ongoing clinical trials to prove safety and efficacy of CRRT products 114
10.2.2.3.4 Government funding and grants to develop cost-effective treatments for AKI patients 114
10.2.2.3.5 Shortage of registered nurses in ICU settings 115
10.2.2.4 Canada 116
10.2.2.4.1 Rising AKI prevalence 116
10.2.2.4.2 Barriers to enter the Canadian CRRT market 116
10.2.2.4.3 High costs of CRRT as compared to IHD 117
10.2.3 ASIA-PACIFIC 118
10.2.3.1 High use of CRRT in Australia and Japan 118
10.2.3.2 Studies and clinical trials to establish the safety and efficacy profile of CRRT 120
10.2.3.3 Dearth of reimbursement and technical expertise 120
10.2.3.4 Japan 122
10.2.3.4.1 Japan focusing on the use of CRRT for non-renal indications 122
10.2.3.4.2 Large number of domestic manufacturers - a barrier to the entry of major players 123
10.2.3.5 China 124
10.2.3.5.1 Rising incidence of AKI and ESRD in the China 124
10.2.3.6 India 125
10.2.3.7 Rest of Asia-Pacific 127
10.2.3.7.1 High utilization of CRRT in Australia 127
10.2.4 REST OF THE WORLD (ROW) 129
10.2.4.1 South Africa 129
10.2.4.2 Latin America and the Middle East 129
11 COMPETITIVE INTELLIGENCE ANALYSIS 131
11.1 COMPETITIVE INTENSITY 131
11.1.1 EVALUATION PARAMETERS AND SCORES 131
11.1.2 SCORING METHODOLOGY 132
11.1.3 COMPETITIVE INTENSITY SCORE, BY COMPANY 132
11.1.3.1 Baxter International Inc. 132
11.1.3.2 NxStage Medical, Inc. 133
11.1.3.3 B. Braun Melsungen AG 134
11.1.3.4 Fresenius Medical Care AG and Co. KGaA 135
11.1.4 COMPETITIVE INTENSITY - MAPPING OF BAXTER, NXSTAGE, B.BRAUN, AND FRESENIUS 136
11.1.5 MARKET SHARE ANALYSIS 137
11.1.5.1 Baxter International Inc. 137
11.1.5.2 Fresenius Medical Care AG and Co. KGaA 138
11.1.5.3 NxStage Medical, Inc. 138
11.2 COMPETITIVE SITUATION AND TRENDS 139
11.2.1 PRODUCT APPROVALS, LAUNCHES, AND ENHANCEMENTS 140
11.2.2 EXPANSIONS 140
11.2.3 ACQUISITIONS 142
11.2.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 143
12 COMPANY PROFILES 144
(Business Overview, Products and Services, Key Insights, Recent Developments, SWOT Analysis, MnM View)*
12.1 INTRODUCTION 144
12.2 BAXTER INTERNATIONAL INC. 145
12.3 FRESENIUS MEDICAL CARE AG and CO. KGAA 148
12.4 NIKKISO CO., LTD. 151
12.5 B. BRAUN MELSUNGEN AG 153
12.6 NXSTAGE MEDICAL, INC. 155
12.7 ASAHI KASEI MEDICAL CO., LTD. (A SUBSIDIARY OF ASAHI KASEI CORPORATION) 157
12.8 BELLCO S.R.L. 159
12.9 INFOMED SA 160
12.10 MEDICA S.P.A 161
12.11 MEDICAL COMPONENTS, INC. 162
12.12 TORAY MEDICAL COMPANY LIMITED 163
*Details on Business Overview, Products and Services, Key Insights, Recent Developments, SWOT Analysis, MnM View might not be

captured in case of unlisted companies.
13 APPENDIX 165
13.1 INSIGHTS OF INDUSTRY EXPERTS 165
13.2 DISCUSSION GUIDE 166
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 170
13.4 AVAILABLE CUSTOMIZATIONS 171
13.5 RELATED REPORTS 172


LIST OF TABLES

TABLE 1
USE OF CRRT AS A GOLD STANDARD FOR TREATMENT OF HEMODYNAMICALLY UNSTABLE PATIENTS IS DRIVING MARKET GROWTH 48
TABLE 2 HIGH PROCEDURAL COST OF CRRT RESTRAINING THE MARKET GROWTH 50
TABLE 3 EVOLUTION OF CRRT FROM SIMPLE RENAL REPLACEMENT TREATMENT TO MULTIPURPOSE THERAPY UNFOLDS NEW GROWTH OPPORTUNITIES 54
TABLE 4 LACK OF SUBSTANTIAL CLINICAL EVIDENCES SUPPORTING EFFICACY OF CRRT POSES A KEY CHALLENGE FOR THE MARKET 56
TABLE 5 AVERAGE SELLING PRICE (ASP) OF CRRT MACHINES, BY MANUFACTURER, 2014 67
TABLE 6 AVERAGE SELLING PRICE OF CRRT BLOODLINES AND DIALYSATE BAGS, 2014 68
TABLE 7 CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 76
TABLE 8 CRRT DIALYSATE and REPLACEMENT FLUIDS MARKET SIZE, BY REGION,
2013-2020 (USD MILLION) 77
TABLE 9 EUROPE: CRRT DIALYSATE and REPLACEMENT FLUIDS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 77
TABLE 10 NORTH AMERICA: CRRT DIALYSATE and REPLACEMENT FLUIDS MARKET SIZE,
BY COUNTRY, 2013-2020 (USD MILLION) 78
TABLE 11 ASIA-PACIFIC: CRRT DIALYSATE and REPLACEMENT FLUIDS MARKET SIZE,
BY COUNTRY, 2013-2020 (USD MILLION) 78
TABLE 12 CRRT MARKET SIZE, BY DISPOSABLES, 2013-2020 (USD MILLION) 79
TABLE 13 CRRT DISPOSABLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 79
TABLE 14 EUROPE: CRRT DISPOSABLES MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 80
TABLE 15 NORTH AMERICA: CRRT DISPOSABLES MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 80
TABLE 16 ASIA-PACIFIC: CRRT DISPOSABLES MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 81
TABLE 17 CRRT SYSTEMS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 83
TABLE 18 EUROPE: CRRT SYSTEMS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 83
TABLE 19 NORTH AMERICA: CRRT SYSTEMS MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 84
TABLE 20 ASIA-PACIFIC: CRRT SYSTEMS MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 84
TABLE 21 CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 87
TABLE 22 CRRT MARKET SIZE FOR CVVH, BY REGION, 2013-2020 (USD MILLION) 88
TABLE 23 NORTH AMERICA: CRRT MARKET SIZE FOR CVVH, BY COUNTRY,
2013-2020 (USD MILLION) 88
TABLE 24 EUROPE: CRRT MARKET SIZE FOR CVVH, BY COUNTRY, 2013-2020 (USD MILLION) 89
TABLE 25 ASIA-PACIFIC: CRRT MARKET SIZE FOR CVVH, BY COUNTRY,
2013-2020 (USD MILLION) 89
TABLE 26 CRRT MARKET SIZE FOR CVVHDF, BY REGION, 2013-2020 (USD MILLION) 90
TABLE 27 NORTH AMERICA: CRRT MARKET SIZE FOR CVVHDF, BY COUNTRY,
2013-2020 (USD MILLION) 91
TABLE 28 EUROPE: CRRT MARKET SIZE FOR CVVHDF, BY COUNTRY,
2013-2020 (USD MILLION) 91
TABLE 29 ASIA-PACIFIC: CRRT MARKET SIZE FOR CVVHDF, BY COUNTRY,
2013-2020 (USD MILLION) 91
TABLE 30 CRRT MARKET SIZE FOR CVVHD, BY REGION, 2013-2020 (USD MILLION) 92
TABLE 31 NORTH AMERICA: CRRT MARKET SIZE FOR CVVHD, BY COUNTRY,
2013-2020 (USD MILLION) 93
TABLE 32 EUROPE: CRRT MARKET SIZE FOR CVVHD, BY COUNTRY,
2013-2020 (USD MILLION) 93
TABLE 33 ASIA-PACIFIC: CRRT MARKET SIZE FOR CVVHD, BY COUNTRY,
2013-2020 (USD MILLION) 93
TABLE 34 CRRT MARKET SIZE FOR SCUF, BY REGION, 2013-2020 (USD MILLION) 94
TABLE 35 NORTH AMERICA: CRRT MARKET SIZE FOR SCUF, BY COUNTRY,
2013-2020 (USD MILLION) 94
TABLE 36 EUROPE: CRRT MARKET SIZE FOR SCUF, BY COUNTRY, 2013-2020 (USD MILLION) 95
TABLE 37 ASIA-PACIFIC: CRRT MARKET SIZE FOR SCUF, BY COUNTRY,
2013-2020 (USD MILLION) 95
TABLE 38 CRRT MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 98
TABLE 39 EUROPE: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 102
TABLE 40 EUROPE: CRRT PRODUCTS MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 102
TABLE 41 EUROPE: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 103
TABLE 42 EUROPE: CRRT MODALITIES MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 103
TABLE 43 GERMANY: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 104
TABLE 44 GERMANY: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 105
TABLE 45 U.K.: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 106
TABLE 46 U.K.: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 106
TABLE 47 FRANCE: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 107
TABLE 48 FRANCE: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 107
TABLE 49 REST OF EUROPE: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 109
TABLE 50 REST OF EUROPE: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 109
TABLE 51 NORTH AMERICA: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 112
TABLE 52 NORTH AMERICA: CRRT PRODUCTS MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 112
TABLE 53 NORTH AMERICA: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 113
TABLE 54 NORTH AMERICA: CRRT MODALITIES MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 113
TABLE 55 U.S.: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 115
TABLE 56 U.S.: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 115
TABLE 57 CANADA: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 117
TABLE 58 CANADA: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 117
TABLE 59 ASIA-PACIFIC: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 120
TABLE 60 ASIA-PACIFIC: CRRT MARKET SIZE FOR PRODUCTS, BY COUNTRY,
2013-2020 (USD MILLION) 121
TABLE 61 ASIA-PACIFIC: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 121
TABLE 62 ASIA-PACIFIC: CRRT MODALITIES MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 121
TABLE 63 JAPAN: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 123
TABLE 64 JAPAN: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 124
TABLE 65 CHINA: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 125
TABLE 66 CHINA: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 125
TABLE 67 INDIA: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 126
TABLE 68 INDIA: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 127
TABLE 69 REST OF ASIA-PACIFIC: CRRT MARKET SIZE, BY PRODUCT,
2013-2020 (USD MILLION) 128
TABLE 70 REST OF ASIA-PACIFIC: CRRT MARKET SIZE, BY MODALITY,
2013-2020 (USD MILLION) 129
TABLE 71 ROW: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION) 130
TABLE 72 ROW: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION) 130
TABLE 73 PRODUCT APPROVALS, LAUNCHES, AND ENHANCEMENTS, 2012-2015 140
TABLE 74 EXPANSIONS, 2012-2015 140
TABLE 75 ACQUISITIONS, 2012-2015 142
TABLE 76 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2012-2015 143


LIST OF FIGURES

FIGURE 1 GLOBAL CRRT MARKET: RESEARCH METHODOLOGY STEPS 20
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 23
FIGURE 3 SUPPLY SIDE 24
FIGURE 4 DEMAND SIDE 25
FIGURE 5 ESTIMATION OF CRRT PROCEDURAL VOLUME 26
FIGURE 6 RESEARCH METHODOLOGY: TOP-DOWN APPROACH {FOR MARKET SIZE ESTIMATION OF DISPOSABLES (BLOODLINE SETS, HEMOFILTERS, AND WATER BAGS)} 27
FIGURE 7 RESEARCH METHODOLOGY: TOP-DOWN APPROACH (FOR MARKET-SIZE ESTIMATION OF CRRT MACHINES) 27
FIGURE 8 RESEARCH METHODOLOGY: BOTTOM-UP APPROACH 28
FIGURE 9 RESEARCH DESIGN 28
FIGURE 10 DATA TRIANGULATION STEPS (TOP-DOWN AND BOTTOM-UP APPROACHES) 29
FIGURE 11 DATA TRIANGULATION METHODOLOGY 30
FIGURE 12 CRRT MARKET SEGMENTATION 32
FIGURE 13 EUROPE TO COMMAND THE LARGEST SHARE OF THE OVERALL CRRT MARKET
IN 2015 33
FIGURE 14 HEMOFILTERS TO FORM THE LARGEST SEGMENT OF CRRT DISPOSABLES MARKET IN 2015 33
FIGURE 15 CVVHDF IS POISED TO BE THE FASTEST-GROWING SEGMENT DURING 2015-2020 34
FIGURE 16 ASIA-PACIFIC IS POISED TO GROW AT THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 35
FIGURE 17 BAXTER WILL CONTINUE TO DOMINATE THE GLOBAL CRRT MARKET DURING FORECAST PERIOD 36
FIGURE 18 HIGH POTENTIAL AND APPLICATIONS OF CRRT TO INCREASE ITS SHARE IN THE HIGH-MARGIN AKI MARKET 37
FIGURE 19 MARKET GROWTH WILL BE DRIVEN BY THE RISING PREVALENCE OF AKI 38
FIGURE 20 DIALYSATE and REPLACEMENT FLUIDS PRODUCT SEGMENT AND CVVH MODALITY SEGMENT WILL DOMINATE THE CRRT MARKET 38
FIGURE 21 CVVH DOMINATES THE ASIA-PACIFIC CRRT MARKET IN 2015 39
FIGURE 22 U.S. TO DOMINATE GLOBAL CRRT MARKET IN THE NEXT FIVE YEARS 40
FIGURE 23 CRRT MARKET SEGMENTATION 42
FIGURE 24 CRRT MARKET SEGMENTATION, BY PRODUCT 42
FIGURE 25 CRRT MARKET SEGMENTATION, BY MODALITY 43
FIGURE 26 CRRT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
FIGURE 27 CRRT MARKET IS EXPECTED TO GROW INLINE WITH RISING PREVALENCE OF AKI 44
FIGURE 28 RISE IN GLOBAL ADOPTION OF CRRT FOR THE TREATMENT OF AKI 45
FIGURE 29 KEY FACTORS AFFECTING REIMBURSEMENT RATES FOR CRRT PROCEDURES 59
FIGURE 30 REIMBURSEMENT SCENARIO OF CRRT IN 2015 60
FIGURE 31 REIMBURSEMENT STRUCTURES VARY WIDELY ACROSS EUROPE 61
FIGURE 32 KEY REGULATORY BODIES INVOLVED IN THE APPROVAL OF NEW CRRT PRODUCTS 63
FIGURE 33 PORTER'S FIVE FORCES ANALYSIS - GLOBAL CRRT MARKET 65
FIGURE 34 DESIGN RECOMMENDATIONS FOR CRRT MACHINES 68
FIGURE 35 UTILIZATION OF CRRT AND DIALYSIS FOR THE TREATMENT OF RENAL PATIENTS
IN ICU, BY REGION (2014) 71
FIGURE 36 RATE OF SWITCHING FROM CRRT TO IHD, BY REGION, 2014 72
FIGURE 37 NUMBER OF CRRT PATIENTS ACROSS THE GLOBE, 2014 73
FIGURE 38 EUROPE WILL DOMINATE THE OVERALL CRRT MARKET (2015 VS. 2020) 75
FIGURE 39 DISPOSABLES FORM THE FASTEST-GROWING BUSINESS WITHIN THE GLOBAL CRRT INDUSTRY 76
FIGURE 40 HEMOFILTERS TO DOMINATE THE CRRT DISPOSABLES MARKET DURING FORECAST PERIOD 79
FIGURE 41 TYPES OF CRRT MODALITIES 86
FIGURE 42 CVVHDF SEGMENT TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD 86
FIGURE 43 EUROPE TO DOMINATE THE OVERALL CVVH MARKET DURING FORECAST PERIOD 87
FIGURE 44 EUROPE IS ESTIMATED TO ACCOUNT FOR THE MAJOR SHARE OF THE TOTAL CVVHDF MARKET IN 2015 90
FIGURE 45 GROWTH IN AKI CASES WORLDWIDE (2010 -2020) 97
FIGURE 46 EUROPE WILL DOMINATE THE OVERALL CRRT MARKET IN THE FORECAST PERIOD 98
FIGURE 47 THE U.S. WILL BE THE MAJOR CONTRIBUTOR TO THE GLOBAL CRRT MARKET IN THE FORECAST PERIOD 99
FIGURE 48 EUROPEAN CRRT MARKET SNAPSHOT: GERMANY WILL CONTINUE TO DOMINATE THE MARKET IN THE FORECAST PERIOD 100
FIGURE 49 GERMANY TO DRIVE THE GROWTH OF CRRT MARKET IN EUROPE 102
FIGURE 50 CVVH ACCOUNTED FOR THE MAJOR SHARE OF THE EUROPEAN CRRT MARKET
IN 2015 103
FIGURE 51 NORTH AMERICAN CRRT MARKET SNAPSHOT: U.S. WILL BE THE MAJOR CONTRIBUTOR TO MARKET GROWTH IN THE FORECAST PERIOD 111
FIGURE 52 ASIA-PACIFIC CRRT MARKET SNAPSHOT: CHINA WILL BE THE FASTEST-GROWING COUNTRY IN THE REGION 119
FIGURE 53 CHINA WILL BE THE FASTEST-GROWING COUNTRY IN THE ASIA-PACIFIC CRRT MARKET IN THE FORECAST PERIOD 122
FIGURE 54 DIALYSATE and REPLACEMENT FLUIDS SEGMENT ACCOUNTS FOR THE MAJOR SHARE OF THE ROW CRRT MARKET, BY PRODUCT, IN 2015 128
FIGURE 55 SCORING METHODOLOGY 132
FIGURE 56 COMPARISON OF COMPETITIVE INTENSITY SCORES: BAXTER, NXSTAGE,
B.BRAUN, AND FRESENIUS 136
FIGURE 57 RELATIVE POSITIONING OF COMPANIES BASED ON COMPETITIVE INTENSITY SCORE AND CRRT FOCUS 136
FIGURE 58 GLOBAL CRRT PRODUCTS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 137
FIGURE 59 GEOGRAPHICAL PRESENCE OF KEY PLAYERS IN CRRT MARKET, 2014 144
FIGURE 60 BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT 145
FIGURE 61 FRESENIUS MEDICAL CARE AG and CO. KGAA: COMPANY SNAPSHOT 148
FIGURE 62 NIKKISO CO., LTD.: COMPANY SNAPSHOT 151
FIGURE 63 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT 153
FIGURE 64 NXSTAGE MEDICAL, INC.: COMPANY SNAPSHOT 155
FIGURE 65 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT 157
FIGURE 66 TORAY GROUP: COMPANY SNAPSHOT 163

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.